Skip to main content
. 2020 Jun 30;12:5085–5098. doi: 10.2147/CMAR.S242135

Figure 6.

Figure 6

MiR-628-5p targeted MAGT1 in glioma cells. (A) The binding sites between miR-628-5p and MAGT1 were forecasted by starBase. (B and C) The interaction between miR-628-5p and MAGT1 was checked by the dual-luciferase reporter assay in glioma cells. (D and E) The Western blot was carried out to check the protein level of MAGT1 in glioma tissues and cells, as well as normal brain tissues and NHA cells. (F and G) The protein level of MAGT1 in control and Sev-treated glioma cells was measured by Western blot. (H and I) The protein level of MAGT1 in glioma cells transfected with anti-miR-628-5p or anti-miR-NC was detected by Western blot. (J and K) The protein level of MAGT1 in glioma cells transfected with Sev, Sev + circ_0002755 or Sev + circ_0002755 + miR-628-5p, as well as the corresponding controls was measured by Western blot. *P< 0.05, **P< 0.01. ***P< 0.001. ****P< 0.0001.